MENU
+Compare
CYCC
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$0.34
Change
-$0.01 (-2.86%)
Capitalization
4.73M

CYCC Cyclacel Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of mechanism-targeted drugs to treat human cancers

Industry Biotechnology
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CYCC with price predictions
Feb 21, 2025

Momentum Indicator for CYCC turns positive, indicating new upward trend

CYCC saw its Momentum Indicator move above the 0 level on February 20, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CYCC just turned positive on February 14, 2025. Looking at past instances where CYCC's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCC advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

CYCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 37 cases where CYCC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CYCC moved below its 50-day moving average on February 18, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CYCC crossed bearishly below the 50-day moving average on January 23, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CYCC entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). CYCC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (9.891) is also within normal values, averaging (251.218).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CYCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CYCC is expected to report earnings to fall 15.65% to -41 cents per share on March 27

Cyclacel Pharmaceuticals CYCC Stock Earnings Reports
Q4'23
Est.
$-0.41
Q3'23
Missed
by $0.13
Q2'23
Beat
by $0.06
Q1'23
Beat
by $0.20
Q4'22
Missed
by $0.12
The last earnings report on November 13 showed earnings per share of -49 cents, missing the estimate of -36 cents. With 77.24K shares outstanding, the current market capitalization sits at 4.73M.
A.I. Advisor
published General Information

General Information

a developer of mechanism-targeted drugs to treat human cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Connell Drive
Phone
+1 908 517-7330
Employees
12
Web
https://cyclacel.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CETX2.040.04
+2.00%
Cemtrex In
SCI78.910.26
+0.33%
Service Corp
TCRX2.17-0.02
-0.91%
TScan Therapeutics
BATRA43.38-0.73
-1.65%
Atlanta Braves Holdings
PNTG25.05-0.71
-2.76%
Pennant Group (The)

CYCC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with CARA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then CARA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
-1.73%
CARA - CYCC
61%
Loosely correlated
-2.93%
CKPT - CYCC
52%
Loosely correlated
-1.57%
MIRM - CYCC
36%
Loosely correlated
-1.34%
ORMP - CYCC
30%
Poorly correlated
-3.15%
IMMP - CYCC
27%
Poorly correlated
-2.54%
More